X4 Pharmaceuticals/$XFOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Ticker
$XFOR
Sector
Primary listing
Employees
45
Headquarters
Website
XFOR Metrics
BasicAdvanced
$377m
-
-$1.38
0.32
-
Price and volume
Market cap
$377m
Beta
0.32
52-week high
$4.83
52-week low
$1.35
Average daily volume
354k
Financial strength
Current ratio
10.18
Quick ratio
9.879
Long term debt to equity
45.426
Total debt to equity
45.861
Interest coverage (TTM)
-10.30%
Profitability
EBITDA (TTM)
-89.685
Gross margin (TTM)
81.82%
Net profit margin (TTM)
-1,106.30%
Operating margin (TTM)
-1,006.31%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-28.33%
Return on equity (TTM)
-104.21%
Valuation
Price to revenue (TTM)
32.019
Price to book
2.24
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
-3.108
Free cash flow yield (TTM)
-32.17%
Free cash flow per share (TTM)
-1.287
Growth
Revenue change (TTM)
-71.26%
Earnings per share change (TTM)
-163.86%
3-year earnings per share growth (CAGR)
-64.74%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs